Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease
Wondering about the differences between all the new medications being prescribed for weight loss
Subgroup analyses showed significant difference in FPG reduction between the exenatide group (1.02 mmol/L, 1.38 to 0.67, I 2 = 0%, P = 0.49) and sitagliptin group, and a significant reduction in liraglutide group compared to sitagliptin groups (1.14 mmol/L, 1.40 to 0.88, I 2 = 0%, P = 0.56) as well
It turned out that most things other than water, protein, and some salts and sugar were performance impairers
Designed for Busy LifestylesWith just one glp-1 patch per day, you can integrate seamlessly into work, travel, or study